Chemotherapy Strategies in Metastatic Pancreatic Ductal

Overview
Pancreatic ductal adenocarcinoma, also known as PDAC, is a lethal disease that is usually diagnosed at an advanced stage with an extremely poor prognosis. Advancements in treatment regimens have improved survival rates, but early diagnosis is crucial for improving outcomes, and awareness of risk factors is vital for early diagnosis. Cytotoxic chemotherapy is the cornerstone of treatment for advanced or metastatic cases, although molecularly targeted therapies and immunotherapies may benefit select patients. Treatment selection depends on several factors, including patients' performance status and comorbidities, which should be considered alongside the efficacy and safety profiles of the different chemotherapy regimens.
This two-part programme provides an overview of the different first- and second-line chemotherapy options.
Complete both modules, answer pre- and post-test questions and start earning CME credits.
This programme is also featured on the COR2ED website, here: Chemotherapy Strategies for Metastatic Pancreatic Ductal Adenocarcinoma
Disclosure of Relevant Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Faculty:
Eileen O’Reilly, MD
Medical Oncologist
Memorial Sloan Kettering Cancer Center
United States
Dr. O’Reilly has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Research: [paid to the institution] Genentech/Roche, BioNTech, AstraZeneca, Arcus, Elicio, Parker Institute, NIH/NCI, Digestive Care, Break Through Cancer, Agenus, Amgen, Revolution Medicines
Consulting: [all uncompensated] Arcus, AstraZeneca, Ability Pharma, Alligator BioSciences, Agenus, BioNTech, Ipsen, Ikena, Merck, Moma Therapeutics, Novartis, Leap Therapeutics, Astellas, BMS, Revolution Medicines, Regeneron, Tango
Efrat Dotan, MD
Medical Oncologist
Penn Medicine, Ann B. Barshinger Cancer Institute
United States
Dr. Dotan has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Research: [paid to the institution] Ipsen, Zymeworks, Lutris, Relay, Lilly, Merck, Dragonfly, Kinate, Leap Therapeutics
Consulting Fees: Amgen, Agenus, Merck, Ipsen, Merus, Olympus
Reviewers/Content Planners/Authors:
- Amy Burdette (GLC) has no relevant relationships to disclose.
- Froukje Sosef (COR2ED): COR2ED receives independent educational grants from several pharmaceutical companies, including Ipsen USA
Learning Objectives
After participating in this activity, learners will be better able to:
- Differentiate the efficacy and safety profiles of chemotherapies for mPDAC and understand how mode of delivery plays a role in this
- Recognize the cause of toxicities and have an awareness of strategies that can be used to improve tolerability and manage side effects whilst maintaining optimal efficacy
Target Audience
GI Medical Oncologists, Gastroenterologists, Internal Medicine, Surgeons, Radiologists, Pathologists and Oncology Nurses, Primary Care Physicians, Community Nurses and any other relevant healthcare professionals.
Accreditation and Credit Designation Statements
In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and COR2ED. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 0.25 nursing contact hour(s). Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credit(s). Approval is valid until April 16, 2026. PAs should claim only the credit commensurate with the extent of their participation in the activity.
Provider(s)/Educational Partner(s)
Commercial Support
This activity is supported by an independent educational grant from Ipsen USA.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and COR2ED. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of ReachMD you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
System Requirements
- Supported Browsers (2 most recent versions):
- - Google Chrome for Windows, Mac OS, iOS, and Android
  - Apple Safari for Mac OS and iOS
  - Mozilla Firefox for Windows, Mac OS, iOS, and Android
  - Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 04/16/2025
Expiration Date: 04/16/2026